高级检索
当前位置: 首页 > 详情页

Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in Western China: a retrospective multi-center study of 7317 female patients

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Endocrine and Breast Surgery, The FirstAffiliated Hospital of Chongqing Medical University, No. 1Youyi Road, Yuzhong District, Chongqing 400016, China [2]Chongqing Key Laboratory of Molecular Oncology andEpigenetics, The First Affiliated Hospital of ChongqingMedical University, Chongqing, China [3]Department of Surgical Oncology, Affiliated Hospital ofNingxia Medical University, Yinchuan, Ningxia, China [4]Department of Breast and Neck Surgery, Affiliated TumorHospital of Xinjiang Medical University, U¨ ru¨mqi, Xinjiang,China [5]Department of Breast Surgery, Affiliated Tumor Hospital ofXinjiang Medical University, Urumqi, Xinjiang, China [6]Department of Breast Surgery, Sichuan Province TumorHospital, Chengdu, Sichuan, China [7]Department of Breast Surgery, Gan Su Province TumorHospital, Lanzhou, Gansu, China [8]Department of Breast Surgery, The First Affiliated Hospitalof Kunming Medical University, Kunming, Yunnan, China [9]Department of Breast Surgery, Guizhou People’s Hospital,Guiyang, Guizhou, China [10]Department of Breast Surgery, GuangXi Medical UniversityAffiliated Tumor Hospital, Nanning, Guangxi, China [11]Department of Breast Surgery, Sichuan Academy of MedicalSciences & Sichuan Provincial People’s Hospital, Chengdu,Sichuan, China [12]Department of Breast Surgery, West China Hospital ofSichuan University, Chengdu, Sichuan, China [13]Mammary Department, Shaanxi Provincial Tumor Hospital,Xi’an, Shaanxi, China [14]Department of Vascular and Endocrine Surgery, XijingHospital of Fourth Military Medical University, Xi’an,Shaanxi, China [15]Department of Breast Surgery, the First Affiliated Hospital ofXi’an Jiaotong University, Xi’an, Shaanxi, China [16]Department of Breast Surgery, the Third Affiliated Hospitalof Kunming Medical University, No. 519, Kunzhou Road,Xishan District, Kunming 650000, Yunnan, China [17]Breast Disease Center, Southwest Hospital, Third MilitaryMedical University, No. 29 Gaotanyan Street,Chongqing 400038, China
出处:
ISSN:

关键词: Breast cancer Mammographic calcification Axillary lymph node metastasis Human epidermal growth factor receptor 2 Hormone receptor

摘要:
Limited information is available regarding the correlations between mammographic calcifications and the epidemiological features of patients with breast cancer living different lifestyles in Western China. Thus, this study aimed to investigate the relationship between mammographic calcifications and the epidemiological characteristics of female patients with breast cancer in Western China. This was a hospital-based, retrospective, multi-center epidemiological study of patients with breast cancer. Using the Western China Clinical Cooperation Group (WCCCG) database, we obtained the records of 7317 patients (with mammographic data) diagnosed with breast cancer between March 2011 and June 2016. These patients were divided into Groups I (mass alone) and II (mass combined with calcification), and their clinical and pathological data were compared. A total of 4211 patients were enrolled in Group I, and 3106 patients were enrolled in Group II. The tumors in Group II were more likely to be larger (P < 0.0001), higher grade (P = 0.0029), estrogen receptor (ER)+/progesterone receptor (PR)- (P = 0.0319), and human epidermal growth factor receptor 2 (HER-2)-positive (P < 0.0001), and to have axillary lymph node metastasis (P = 0.0033) than those in Group I. Regarding treatment, patients in Group II were more likely to have undergone chemotherapy (P = 0.0108) and anti-HER2 therapy (P = 0.0102), whereas patients in Group I were more likely to have undergone endocrine therapy (P < 0.0001). In conclusion, mammographic calcifications in tumors were associated with distinct clinicopathologic characteristics and aggressive treatments.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2017]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Department of Endocrine and Breast Surgery, The FirstAffiliated Hospital of Chongqing Medical University, No. 1Youyi Road, Yuzhong District, Chongqing 400016, China
通讯作者:
通讯机构: [1]Department of Endocrine and Breast Surgery, The FirstAffiliated Hospital of Chongqing Medical University, No. 1Youyi Road, Yuzhong District, Chongqing 400016, China [2]Chongqing Key Laboratory of Molecular Oncology andEpigenetics, The First Affiliated Hospital of ChongqingMedical University, Chongqing, China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in Western China: a retrospective multi-center study of 7317 female patients [2]Nuclear Morphological Characteristics in Breast Cancer: Correlation with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 [3]Nuclear Morphological Characteristics in Breast Cancer: Correlation with Hormone Receptor and Human Epidermal Growth Factor Receptor 2. [4]Efficacy and safety of tucidinostat in patients with advanced hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: real-world insights [5]Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial [6]A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients [7]Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study. [8]Peritumoral edema enhances MRI-based deep learning radiomic model for axillary lymph node metastasis burden prediction in breast cancer [9]Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer [10]Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号